Ibutamoren | CAS#159634-47-6 | growth hormone secretagogue

MedKoo Cat#: 596400 | Name: Ibutamoren

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ibutamoren, also known as MK-677 (L-163,191), is a drug which acts as a potent, orally active growth hormone secretagogue, mimicking the GH stimulating action of the endogenous hormone ghrelin. It has been demonstrated to increase the release of, and produces sustained increases in plasma levels of several hormones including growth hormone and IGF-1, but without affecting cortisol levels.It is currently under development as a potential treatment for reduced levels of these hormones, such as in growth hormone deficient children or elderly adults, and human studies have shown it to increase both muscle mass and bone mineral density, making it a promising therapy for the treatment of frailty in the elderly. It also alters metabolism of body fat and so may have application in the treatment of obesity.

Chemical Structure

Ibutamoren

CAS#159634-47-6 (free base)

Theoretical Analysis

MedKoo Cat#: 596400

Name: Ibutamoren

CAS#: 159634-47-6 (free base)

Chemical Formula: C27H36N4O5S

Exact Mass: 528.2406

Molecular Weight: 528.66

Elemental Analysis: C, 61.34; H, 6.86; N, 10.60; O, 15.13; S, 6.06

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

159752-10-0 (mesylate) 159634-47-6 (free base)

Synonym

Ibutamoren; L 163191; L-163191; L163191; MK-677; MK 677; MK677;

IUPAC/Chemical Name

(R)-2-amino-N-(3-(benzyloxy)-1-(1-(methylsulfonyl)spiro[indoline-3,4'-piperidin]-1'-yl)-1-oxopropan-2-yl)-2-methylpropanamide

InChi Key

UMUPQWIGCOZEOY-JOCHJYFZSA-N

InChi Code

InChI=1S/C27H36N4O5S/c1-26(2,28)25(33)29-22(18-36-17-20-9-5-4-6-10-20)24(32)30-15-13-27(14-16-30)19-31(37(3,34)35)23-12-8-7-11-21(23)27/h4-12,22H,13-19,28H2,1-3H3,(H,29,33)/t22-/m1/s1

SMILES Code

CC(C)(N)C(N[C@H](COCC1=CC=CC=C1)C(N2CCC3(CC2)CN(S(=O)(C)=O)C4=C3C=CC=C4)=O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 528.66 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Van Wagoner RM, Eichner A, Bhasin S, Deuster PA, Eichner D. Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet. JAMA. 2017 Nov 28;318(20):2004-2010. doi: 10.1001/jama.2017.17069. Erratum in: JAMA. 2018 Feb 20;319(7):724. PubMed PMID: 29183075; PubMed Central PMCID: PMC5820696. 2: Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018 Jan;6(1):45-53. doi: 10.1016/j.sxmr.2017.02.004. Epub 2017 Apr 8. Review. PubMed PMID: 28400207; PubMed Central PMCID: PMC5632578. 3: Harmatz ES, Stone L, Lim SH, Lee G, McGrath A, Gisabella B, Peng X, Kosoy E, Yao J, Liu E, Machado NJ, Weiner VS, Slocum W, Cunha RA, Goosens KA. Central Ghrelin Resistance Permits the Overconsolidation of Fear Memory. Biol Psychiatry. 2017 Jun 15;81(12):1003-1013. doi: 10.1016/j.biopsych.2016.11.009. Epub 2016 Nov 29. PubMed PMID: 28010876; PubMed Central PMCID: PMC5447505. 4: Patel K, Joharapurkar A, Dhanesha N, Patel V, Kshirsagar S, Raval P, Raval S, Jain MR. Thyroid hormone modulates food intake and glycemia via ghrelin secretion in Zucker fatty rats. Drug Res (Stuttg). 2014 Oct;64(10):523-9. doi: 10.1055/s-0033-1363222. Epub 2013 Dec 19. PubMed PMID: 24357139. 5: Schellekens H, McNamara O, Dinan TG, McCarthy JV, McGlacken GP, Cryan JF. Semagacestat, a γ-secretase inhibitor, activates the growth hormone secretagogue (GHS-R1a) receptor. J Pharm Pharmacol. 2013 Apr;65(4):528-38. doi: 10.1111/jphp.12010. Epub 2012 Nov 27. PubMed PMID: 23488781. 6: Adunsky A, Chandler J, Heyden N, Lutkiewicz J, Scott BB, Berd Y, Liu N, Papanicolaou DA. MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study. Arch Gerontol Geriatr. 2011 Sep-Oct;53(2):183-9. doi: 10.1016/j.archger.2010.10.004. Epub 2010 Nov 9. PubMed PMID: 21067829. 7: Ceda GP, Dall'Aglio E, Morganti S, Denti L, Maggio M, Lauretani F, Andrea A, Ceresini G, Cattabiani C, Valenti G. Update on new therapeutic options for the somatopause. Acta Biomed. 2010;81 Suppl 1:67-72. Review. PubMed PMID: 20518193. 8: Hakim RM, Ikizler TA. Anabolic interventions in ESRD: light at the end of the tunnel? Am J Kidney Dis. 2009 Aug;54(2):201-4. doi: 10.1053/j.ajkd.2009.04.018. Epub 2009 Jun 25. PubMed PMID: 19556045. 9: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2009 Mar;31(2):107-46. PubMed PMID: 19455266. 10: Webster J. Rejuvenation in older adults receiving oral ghrelin. Ann Intern Med. 2009 May 5;150(9):654-5; author reply 655. PubMed PMID: 19414853. 11: Gaugg M. Rejuvenation in older adults receiving oral ghrelin. Ann Intern Med. 2009 May 5;150(9):654; author reply 655. PubMed PMID: 19414852. 12: Rafael H. Rejuvenation in older adults receiving oral ghrelin. Ann Intern Med. 2009 May 5;150(9):653-4; author reply 655. PubMed PMID: 19414850. 13: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2009 Jan-Feb;31(1):47-57. PubMed PMID: 19357798. 14: Hanauer SB. Sarcopenia and the elusive fountain of youth. Nat Clin Pract Gastroenterol Hepatol. 2009 Jan;6(1):1. doi: 10.1038/ncpgasthep1320. PubMed PMID: 19127276. 15: Sevigny JJ, Ryan JM, van Dyck CH, Peng Y, Lines CR, Nessly ML; MK-677 Protocol 30 Study Group. Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial. Neurology. 2008 Nov 18;71(21):1702-8. doi: 10.1212/01.wnl.0000335163.88054.e7. PubMed PMID: 19015485. 16: Blackman MR. Use of growth hormone secretagogues to prevent or treat the effects of aging: not yet ready for prime time. Ann Intern Med. 2008 Nov 4;149(9):677-9. PubMed PMID: 18981489. 17: Nass R, Pezzoli SS, Oliveri MC, Patrie JT, Harrell FE Jr, Clasey JL, Heymsfield SB, Bach MA, Vance ML, Thorner MO. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008 Nov 4;149(9):601-11. PubMed PMID: 18981485; PubMed Central PMCID: PMC2757071. 18: Summaries for patients. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Ann Intern Med. 2008 Nov 4;149(9):I-36. PubMed PMID: 18981483. 19: Holst B, Frimurer TM, Mokrosinski J, Halkjaer T, Cullberg KB, Underwood CR, Schwartz TW. Overlapping binding site for the endogenous agonist, small-molecule agonists, and ago-allosteric modulators on the ghrelin receptor. Mol Pharmacol. 2009 Jan;75(1):44-59. doi: 10.1124/mol.108.049189. Epub 2008 Oct 15. PubMed PMID: 18923064. 20: Devin JK, Young PP. The effects of growth hormone and insulin-like growth factor-1 on the aging cardiovascular system and its progenitor cells. Curr Opin Investig Drugs. 2008 Sep;9(9):983-92. Review. PubMed PMID: 18729005.